Researchers identified five distinct molecular subtypes of Alzheimer’s disease using proteomic sequencing, suggesting personalized treatment approaches based on each subtype’s unique genetic and pathological characteristics.
Ubiquigent collaborates with Imperial College London on DUB probe discovery to facilitate preclinical and clinical target engagement studies
Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today
October 4, 2023